Nov 16 (Reuters) – Helus Pharma said on Monday its experimental psychedelic drug showed statistically significant improvement in depression symptoms compared with placebo in a late-stage trial in patients with major depressive disorder.
The study enrolled 222 adults with moderate to severe major depression.
After six weeks, patients on HLP003 improved by 19.5 points on a standard depression scale, while patients on placebo improved by 11.9 points, the company said.
However, shares fell 20% in premarket trading.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Jonathan Ananda)

